Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3437 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-20

Study Completion Date

2016-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this survey is to evaluate the safety and efficacy of long-term use of azilsartan tablets (Azilva Tablets) in patients with hypertension in a routine clinical setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

NCT02100319

Hypertension

COMPLETED

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering

NCT01609959

Hypertension

COMPLETED PHASE4

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

NCT02079805

Essential Hypertension Complicated by Type 2 Diabetes Mellitus

COMPLETED PHASE4

Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers

NCT02786082

Hypertension

COMPLETED PHASE1

A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure

NCT05107960

Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This surveillance was designed to evaluate the safety and efficacy of long-term use of azilsartan tablets (Azilva Tablets) in hypertensive patients in daily medical practice.

The usual dosage for adult is 20 mg of azilsartan administered orally once daily. The dose can be adjusted according to the patient's age and condition. The maximum daily dose is 40 mg.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Azilsartan

Azilsartan 20 mg - 40 mg, tablet, orally, once daily for up to 12 months in participants based upon the disease severity. Participants will receive interventions as part of routine medical care.

Azilsartan

Intervention Type DRUG

Azilsartan tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Azilsartan

Azilsartan tablets

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Azilva Tablets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypertensive patients

Exclusion Criteria

1. Patients with a history of hypersensitivity to any of the ingredients of Azilsartan
2. Patients who are pregnant or having possibilities of being pregnant

Eligible Sex

ALL

Accepts Healthy Volunteers

No